Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival

Giulia Di Lullo, Magda Marcatti, Silvia Heltai, Emanuela Brunetto, Cristina Tresoldi, Attilio Bondanza, Chiara Bonini, Maurilio Ponzoni, Giovanni Tonon, Fabio Ciceri, Claudio Bordignon, Maria Pia Protti

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III and relapsed/refractory MM patients compared with healthy donors and patients with asymptomatic or stage I/II disease. Th22 cells cloned from the BM of MM patients were CCR6+CXCR4+CCR4+CCR10-and produced IL-22 and IL-13 but not IL-17. Furthermore, polyfunctional Th22-Th2 and Th22-Th1 clones were identified based on the co-expression of additional chemokine receptors and cytokines (CRTh2 or CXCR3 and IL-5 or interferon gamma [IFNγ], respectively). A fraction of MM cell lines and primary tumors aberrantly expressed the IL-22RA1 and IL-22 induced STAT-3 phosphorylation, cell growth, and resistance to drug-induced cell death in MM cells. IL-13 treatment of normal BM mesenchymal stromal cells (MSCs) induced STAT-6 phosphorylation, adhesion molecule upregulation, and increased IL-6 production and significantly favored MM cell growth compared with untreated BM MSCs. Collectively, our data show that increased frequency of IL-22+IL-17-IL-13+ T cells correlates with poor prognosis in MM through IL-22 and IL-13 protumor activity and suggest that interference with IL-22 and IL-13 signaling pathways could be exploited for therapeutic intervention.

Original languageEnglish
JournalOncoImmunology
Volume4
Issue number5
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Interleukin-13
Multiple Myeloma
Cell Survival
Mesenchymal Stromal Cells
Growth
Interleukin-17
Neoplasms
Bone Marrow
Phosphorylation
T-Lymphocytes
Chemokine Receptors
Interleukins
Interleukin-5
Tumor Cell Line
Drug Resistance
Bone Marrow Cells
Dendritic Cells
Interferon-gamma
interleukin-22
Cell Differentiation

Keywords

  • Bone marrow mesenchymal stromal cells
  • Bone marrow microenvironment
  • CD4 T helper lymphocytes
  • IL-22RA1
  • Interleukin-13
  • Interleukin-22
  • Multiple myeloma
  • Th22 cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. / Lullo, Giulia Di; Marcatti, Magda; Heltai, Silvia; Brunetto, Emanuela; Tresoldi, Cristina; Bondanza, Attilio; Bonini, Chiara; Ponzoni, Maurilio; Tonon, Giovanni; Ciceri, Fabio; Bordignon, Claudio; Protti, Maria Pia.

In: OncoImmunology, Vol. 4, No. 5, 01.01.2015.

Research output: Contribution to journalArticle

Lullo, Giulia Di ; Marcatti, Magda ; Heltai, Silvia ; Brunetto, Emanuela ; Tresoldi, Cristina ; Bondanza, Attilio ; Bonini, Chiara ; Ponzoni, Maurilio ; Tonon, Giovanni ; Ciceri, Fabio ; Bordignon, Claudio ; Protti, Maria Pia. / Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. In: OncoImmunology. 2015 ; Vol. 4, No. 5.
@article{58f685978f49495fb454d061d9053528,
title = "Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival",
abstract = "There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III and relapsed/refractory MM patients compared with healthy donors and patients with asymptomatic or stage I/II disease. Th22 cells cloned from the BM of MM patients were CCR6+CXCR4+CCR4+CCR10-and produced IL-22 and IL-13 but not IL-17. Furthermore, polyfunctional Th22-Th2 and Th22-Th1 clones were identified based on the co-expression of additional chemokine receptors and cytokines (CRTh2 or CXCR3 and IL-5 or interferon gamma [IFNγ], respectively). A fraction of MM cell lines and primary tumors aberrantly expressed the IL-22RA1 and IL-22 induced STAT-3 phosphorylation, cell growth, and resistance to drug-induced cell death in MM cells. IL-13 treatment of normal BM mesenchymal stromal cells (MSCs) induced STAT-6 phosphorylation, adhesion molecule upregulation, and increased IL-6 production and significantly favored MM cell growth compared with untreated BM MSCs. Collectively, our data show that increased frequency of IL-22+IL-17-IL-13+ T cells correlates with poor prognosis in MM through IL-22 and IL-13 protumor activity and suggest that interference with IL-22 and IL-13 signaling pathways could be exploited for therapeutic intervention.",
keywords = "Bone marrow mesenchymal stromal cells, Bone marrow microenvironment, CD4 T helper lymphocytes, IL-22RA1, Interleukin-13, Interleukin-22, Multiple myeloma, Th22 cells",
author = "Lullo, {Giulia Di} and Magda Marcatti and Silvia Heltai and Emanuela Brunetto and Cristina Tresoldi and Attilio Bondanza and Chiara Bonini and Maurilio Ponzoni and Giovanni Tonon and Fabio Ciceri and Claudio Bordignon and Protti, {Maria Pia}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/2162402X.2015.1005460",
language = "English",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "5",

}

TY - JOUR

T1 - Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival

AU - Lullo, Giulia Di

AU - Marcatti, Magda

AU - Heltai, Silvia

AU - Brunetto, Emanuela

AU - Tresoldi, Cristina

AU - Bondanza, Attilio

AU - Bonini, Chiara

AU - Ponzoni, Maurilio

AU - Tonon, Giovanni

AU - Ciceri, Fabio

AU - Bordignon, Claudio

AU - Protti, Maria Pia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III and relapsed/refractory MM patients compared with healthy donors and patients with asymptomatic or stage I/II disease. Th22 cells cloned from the BM of MM patients were CCR6+CXCR4+CCR4+CCR10-and produced IL-22 and IL-13 but not IL-17. Furthermore, polyfunctional Th22-Th2 and Th22-Th1 clones were identified based on the co-expression of additional chemokine receptors and cytokines (CRTh2 or CXCR3 and IL-5 or interferon gamma [IFNγ], respectively). A fraction of MM cell lines and primary tumors aberrantly expressed the IL-22RA1 and IL-22 induced STAT-3 phosphorylation, cell growth, and resistance to drug-induced cell death in MM cells. IL-13 treatment of normal BM mesenchymal stromal cells (MSCs) induced STAT-6 phosphorylation, adhesion molecule upregulation, and increased IL-6 production and significantly favored MM cell growth compared with untreated BM MSCs. Collectively, our data show that increased frequency of IL-22+IL-17-IL-13+ T cells correlates with poor prognosis in MM through IL-22 and IL-13 protumor activity and suggest that interference with IL-22 and IL-13 signaling pathways could be exploited for therapeutic intervention.

AB - There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III and relapsed/refractory MM patients compared with healthy donors and patients with asymptomatic or stage I/II disease. Th22 cells cloned from the BM of MM patients were CCR6+CXCR4+CCR4+CCR10-and produced IL-22 and IL-13 but not IL-17. Furthermore, polyfunctional Th22-Th2 and Th22-Th1 clones were identified based on the co-expression of additional chemokine receptors and cytokines (CRTh2 or CXCR3 and IL-5 or interferon gamma [IFNγ], respectively). A fraction of MM cell lines and primary tumors aberrantly expressed the IL-22RA1 and IL-22 induced STAT-3 phosphorylation, cell growth, and resistance to drug-induced cell death in MM cells. IL-13 treatment of normal BM mesenchymal stromal cells (MSCs) induced STAT-6 phosphorylation, adhesion molecule upregulation, and increased IL-6 production and significantly favored MM cell growth compared with untreated BM MSCs. Collectively, our data show that increased frequency of IL-22+IL-17-IL-13+ T cells correlates with poor prognosis in MM through IL-22 and IL-13 protumor activity and suggest that interference with IL-22 and IL-13 signaling pathways could be exploited for therapeutic intervention.

KW - Bone marrow mesenchymal stromal cells

KW - Bone marrow microenvironment

KW - CD4 T helper lymphocytes

KW - IL-22RA1

KW - Interleukin-13

KW - Interleukin-22

KW - Multiple myeloma

KW - Th22 cells

UR - http://www.scopus.com/inward/record.url?scp=84938652921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938652921&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1005460

DO - 10.1080/2162402X.2015.1005460

M3 - Article

AN - SCOPUS:84938652921

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 5

ER -